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Background—We investigated the potential of magnetic resonance imaging (MRI) to track magnetically labeled
mesenchymal stem cells (MR-MSCs) in a swine myocardial infarction (MI) model.
Methods and Results—Adult farm pigs (n5) were subjected to closed-chest experimental MI. MR-MSCs (2.8 to 16107
cells) were injected intramyocardially under x-ray fluoroscopy. MRIs were obtained on a 1.5T MR scanner to
demonstrate the location of the MR-MSCs and were correlated with histology. Contrast-enhanced MRI demonstrated
successful injection in the infarct and serial MSC tracking was demonstrated in two animals.
Conclusion—MRI tracking of MSCs is feasible and represents a preferred method for studying the engraftment of MSCs
in MI. (Circulation. 2003;107:2290-2293.)
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Because of the limited regenerative capacity of the heartmuscle, mesenchymal stem cells (MSCs), found in bone
marrow, may have enormous therapeutic potential for limit-
ing infarct size and restoring cardiac function after irrevers-
ible ischemic injury. Most techniques for the study of stem
cell transplantation in animal models require histological
analysis to determine the fate and migration of cells.1–5 Thus,
the number and location of MSCs delivered using intramyo-
cardial delivery techniques can only be estimated postmor-
tem. The recent ability to label MSCs6 with magnetic reso-
nance imaging (MRI)–visible contrast agents should enable
serial tracking and quantification of MSC transplantation
noninvasively with high spatial resolution. Thus, the purpose
of this study was to determine whether magnetically labeled
MSCs injected intramyocardially could be detected and
tracked noninvasively by MRI in a swine model of myocar-
dial infarction.
Methods
Animal Model
Animal studies were approved by the Institutional Animal Care and
Use Committee. The evening before creation of a myocardial
infarction (MI), 5 farm pigs (25 to 35 kg; Archer Farms, Belcamp,
Md) received aspirin (325 mg) and diltiazem (180 mg sustained
release) orally. Animals were sedated with acepromazine, ketamine,
and atropine; induced with thiopental; and then intubated and
mechanically ventilated with oxygen and isoflurane. To create MI,
cardiac catheterization was performed via a 9F carotid sheath, and a
2.0 or 2.520-mm coronary angioplasty balloon (Cordis, Inc) was
inflated in the left anterior descending (LAD) artery beyond the first
diagonal branch to occlude LAD flow for 60 minutes, followed by
reperfusion. After allowing for stabilization, allogeneic MSCs were
given by intramyocardial injection using a deflectable guiding
catheter and a helical needle (Biocardia, Inc). In 4 animals, MR-
MSCs were injected; 1 control animal received nonlabeled MSCs.
Magnetically Labeled MSCs
Swine mesenchymal stem cells were isolated and cultured as
previously described.7 The MSCs were culture-expanded 2 or 3
passages in vitro, yielding up to 400 million cells, which were
frozen and thawed for use. In two studies, before freezing, the
MSCs were fluorescently labeled with DiI (1,1-dioctadecyl-
3,3,33-testramethylindocarbocyanine perchlorate) and DAPI
(4,6-Diamidino-2-phenylindole), which preferentially stain cells
membranes and nuclei, respectively.
The swine MSCs were magnetically labeled by incubation with
ferumoxides injectable solution (25 g Fe/mL, Feridex, Berlex
Laboratories) in culture medium for 24 to 48 hours with 375 ng/mL
poly-L-lysine (PLL; average MW275 kDa) added 1 hour before
cell incubation. Magnetic labeling was histologically assessed using
Prussian Blue.
After magnetic labeling, Feridex-labeled MSCs (MR-MSCs) were
washed in phosphate-buffered saline (PBS, pH7.4), trypsinized,
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washed, and resuspended in 0.01 mol/L PBS at a concentration of 7
to 10106 cells/mL.
MR Imaging
All imaging was performed under general anesthesia on a 1.5T MR
scanner (CV/i, GE Medical Systems) using ECG gating, with the
animal in right decubitus and a 4-channel phased-array coil wrapped
around the chest wall. All images were acquired during suspension
of the ventilator.
To assess MR-MSC detection, animals were imaged within the
first 24 hours after intramyocardial MR-MSC injection. In addition,
one animal was reimaged at 1 week and another at 3 weeks to detect
MR-MSC migration. Pulse parameters for cardiac gated, fast
gradient-recalled echo (FGRE), and double-inversion recovery, fast
spin echo (FSE) were optimized to detect MR-MSCs.
The size and location of the myocardial infarction was assessed by
using delayed-enhancement MRI (DE-MRI) with image parameters
of 7.8-ms repetition time (TR); 3.4-ms echo time (TE); 25° flip angle
(FA); 256192 image matrix; 5-mm slice thickness; 32-kHz band-
width (BW); 28-cm field-of-view (FOV); 2 slice averages (NSA);
and 250-ms inversion delay (TI). Gd-DTPA (Magnevist, Berlex
Laboratories; 0.2 mmol/kg bolus) was injected intravenously; DE-
MRI was acquired 15 minutes after contrast. The number of injection
sites visualized by MRI was determined by a consensus of two
observers blinded to the location or number of injections. The
MR-MSC lesion volume was determined using planimetry of FGRE
MRI (Cinetool, GE). The contrast of the MR-MSC hypointense
lesion from the FGRE images, acquired within 24 hours of MR-MSC
injection and at 1 week after injection, was determined using the
difference in signal intensity between the hypointense and normal
myocardium divided by signal intensity of the normal region.
Postmortem Analysis
After humane euthanasia, the heart was excised and sliced along the
short-axis plane. Histology corresponding to MRI slices that dem-
onstrated MR-MSCs lesions was performed.
Results
In Vitro Magnetic Labeling of MSCs
MSCs appeared to be unaffected by magnetic labeling, and
viability immediately before injection, as determined by
trypan blue exclusion, was 95%. Prussian Blue staining of
PLL-Feridex–labeled MSCs revealed the presence of numer-
ous iron-containing vesicles or endosomes in the cytoplasm.
Optimized MR Imaging Parameters
Hypointense lesions attributable to MR-MSCs were better
visualized on FGRE images than on FSE images (Figure, A
and B). FGRE image parameters were as follows: TR/TE/
FA6.0 ms/1.6 ms/20°; 512512 image matrix; 5-mm slice
thickness; 32-kHz BW; 28-cm FOV; and 4 NSA. Images
were acquired in the same imaging planes using an ECG-
gated FSE pulse sequence with blood suppression. Optimized
imaging parameters were as follows: TR/TE1463 ms/85
ms: echo train length32; 256256 image matrix; 62.5-kHz
BW; and 2 NSA. Due to the apical location of the MR-MSC
injections, the hypoenhancing lesions were best appreciated
on long-axis images (Figure, A and B).
Intramyocardial Injections
A total of 50 intramyocardial injections (Table) were per-
formed under x-ray fluoroscopy. One injection in each of four
animals was intentionally placed far from the infarct territory.
Twenty-four of the 34 MR-MSC injections were visualized
by MRI, but none of the nonlabeled injections were seen. One
of four injections placed remote from the infarction could not
be detected with MRI. DE-MRI confirmed the presence of
MR-MSC injection sites within the infarct (ie, hypoenhancing
lesion within hyperenhancing infarcted tissue; Figure, C).
Images of MR-MSC injection sites within 24 hours after
injection appeared as ovoid hypoenhancing lesions with sharp
borders (Figure, D). At 1 week and 3 weeks after injection,
the delineation of the borders was less clear (Figure, E). At 1
week after MR-MSC injection, all lesions that were detected
within 24 hours after injection could still be detected. The
size of the lesions expanded by 15% over 1 week. The
contrast of the lesion decreased by 244% in concert with the
lesions’ expansion at 1 week. However, at 3 weeks after
injection, some wall thinning had occurred in the region to the
extent that only 25.8% of the original MR-MSC lesions could
be detected. Multiple hypointense lesions that were present
within 24 hours of MR-MSC injection could no longer be
appreciated at 3 weeks. Instead, a hypointense signal was
appreciated along the rim of the endocardial border adjacent
to the area of wall thinning and myocardial infarction.
Postmortem Analysis
Prussian blue staining consistently showed dense intracellular
iron labeling in large round cells, with iron exclusion from the
nucleus. Cells were detected in sections corresponding to
lesions seen on MRI. In addition, fluorescently labeled MSCs
were demonstrated on histological sections adjacent to Prus-
sian Blue staining for Feridex-labeled MSCs (Figure, F
through J), indicating that Feridex remained within the
originally labeled cells. Intramyocardial injection sites could
not be appreciated grossly postmortem. However, distinct
“needle-tract” lesions representing MR-MSCs were present
on the Prussian blue-stained sections (Figure, F).
Discussion
A high degree of magnetic labeling of MSCs was achieved
using poly-L-lysine as a transfection agent. PLL coating of the
Feridex effectively chaperones the iron oxide nanoparticles
across the cellular membrane.8 Cell viability remained95%
after Feridex/PLL labeling, with no increased apoptosis at 3
days after labeling, no alterations to proliferation, or in-
creased toxicity for at least 9 days as determined by MTT
(3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide) assay.8
A major difficulty with x-ray fluoroscopic delivery of
MSCs for cardiac regeneration is the inability to determine
whether an injection was successful. Labeling MSCs with an
MR contrast agent allows determination of the size and
location of each intramyocardial injection to determine the
extent of MSC retention. This labeling technique uses an
approved contrast agent with a non–species-specific transfec-
tion technique, the imaging protocol uses a standard clinical
MRI scanner, and the swine model uses devices under
development for human trials in a closed-chest MI model that
is minimally invasive and thus more comparable to human
MI pathology than open-chest rodent models. Thus, this study
demonstrates the feasibility of MR-MSC labeling for future
clinical trials of cellular cardiomyoplasty.
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In previous swine MI studies, 10 to 20 injection sites of
20 million cells per site have demonstrated the ability of
swine MSCs to engraft in the infarct, differentiate toward a
cardiomyocyte phenotype, and improve global cardiac func-
tion compared with control animals.9 In the present study, we
were able to detect MSC injection sites at approximately one
third to one half the therapeutic dose of previous studies,
lending promise to the ability to detect small numbers of
MSCs by MRI.
Although this decreased dose of MSCs did not prevent wall
thinning at 3 weeks in one animal, serial tracking of MSC
lesions in two animals showed increasing lesion size with a
concurrent decrease in lesion contrast that could result from
the following: (1) MSC division with decreasing Feridex
Representative hypointense lesions in FSE (A), FGRE (B), and DE-MRI (C) of MR-MSC injection sites (arrows) within 24 hours of injec-
tion. MR-MSCs were injected in the infarct (MI, hyperintense region in C). Long-axis MRIs showing hypointense lesions (arrows) caused
by MR-MSCs acquired within 24 hours (D) and 1 week (E) of injection with inset at right demonstrating expansion of lesion over 1
week. Needle tract (arrow) of MR-MSCs is demonstrated in histological section at 1 week after injection with Prussian Blue staining (F)
as cells with blue iron inclusions (arrowhead) that are excluded from nucleus (G). Iron inclusion from DAB-enhanced Prussian Blue
staining (H) matches co-labeling with DiI (I) and DAPI fluorescent dyes (J) on adjacent histological sections at 20 magnification at 24
hours after MSC injection in another animal, indicating Feridex is still contained within original MSCs. LV indicates left ventricle; RV,
right ventricle.
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concentration/MSC; (2) migration of MSCs with decreasing
Feridex concentration/voxel; or (3) a combination of MSC
migration and division. Decreased contrast could result from
MSC death and removal but would not explain the expanded
lesion volume without reuptake of iron by macrophages,
which contradicts the histological picture in this study. Future
studies will further delineate the fate of injected MR-MSCs
and will incorporate noninvasive tagging methods to monitor
myocardial function after MSC engraftment in the MI. The
recent report of autologous intracoronary bone marrow trans-
plantation in MI patients10 demonstrates the need for nonin-
vasive techniques to monitor MSC delivery and response to
treatment in future clinical trials.
Limitations
In this study, using a limited number of injections per animal,
we were unable to visualize by MRI 30% of the injections
performed under x-ray fluoroscopy in each animal.
Because of the large T2 effects exerted by Feridex, only a
small quantity of labeled MSCs (10 to 20 MSCs/voxel) is
required to cause a hypointense lesion. The “missed” MR
visualization of injection sites could be explained by four
possibilities: areas where (1) intramyocardial delivery failed;
(2) an extremely low MR-MSC concentration was injected;
(3) the saline medium alone (without MR-MSCs) was in-
jected; or (4) multiple injections occurred at the same
anatomical location.
Conclusion
MR tracking of MR-MSCs is feasible and represents a
method for noninvasively tracking the quantity and location
of intramyocardial delivery after MI. The ability to perform
serial assessment of infarct size and regional cardiac function
by MRI while tracking MR-MSCs offers a method to study
the optimum protocols for delivery of MSCs for cardiac
regeneration.
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MRI Visualization of Intramyocardial MSC Injections
Study
MSCs/mL of
PBS
No. of 1-mL
Injections
Total MSCs
Injected
MRI
Visualized
1 7106 4 2.8107 3
2 7106 6 4.2107 4
3 7106 11 7.7107 7
4 1107 13 1.3108 10
5* 1107 16 1.6108 0
*Unlabeled MSCs.
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